Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 331

1.

The Future of Clinical Trial Design: The Transition from Hard Endpoints to Value-Based Endpoints.

Kruizinga MD, Stuurman FE, Groeneveld GJ, Cohen AF.

Handb Exp Pharmacol. 2019 Nov 10. doi: 10.1007/164_2019_302. [Epub ahead of print]

PMID:
31707472
2.

Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: an exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis.

Kruizinga MD, Birkhoff WAJ, van Esdonk MJ, Klarenbeek NB, Cholewinski T, Nelemans T, Dröge MJ, Cohen AF, Zuiker RGJA.

Br J Clin Pharmacol. 2019 Oct 28. doi: 10.1111/bcp.14156. [Epub ahead of print]

PMID:
31658494
3.

Objective Assessment of Fitness to Perform (FTOP) After Surgical Night Shifts in the Netherlands: An Observational Study Using the Validated FTOP Self-test in Daily Surgical Practice.

Tummers FHMP, Huizinga CRH, Stockmann HBAC, Hamming JF, Cohen AF, van der Bogt KEA; FTOP Collaborators*.

Ann Surg. 2019 Nov;270(5):930-936. doi: 10.1097/SLA.0000000000003517.

PMID:
31567505
4.

Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?

In 't Veld AE, Grievink HW, Saghari M, Stuurman FE, de Kam ML, de Vries APJ, de Winter BCM, Burggraaf J, Cohen AF, Moerland M.

Int J Mol Sci. 2019 Sep 23;20(19). pii: E4710. doi: 10.3390/ijms20194710.

5.

Retinal oximetry and fractal analysis of capillary maps in sickle cell disease patients and matched healthy volunteers.

Birkhoff WAJ, van Manen L, Dijkstra J, De Kam ML, van Meurs JC, Cohen AF.

Graefes Arch Clin Exp Ophthalmol. 2019 Sep 16. doi: 10.1007/s00417-019-04458-0. [Epub ahead of print]

PMID:
31529320
6.

Rare disease specialists and clinical pharmacologists unite: Increase collection of longitudinal data!

Santen GWE, Cohen AF.

Br J Clin Pharmacol. 2019 Nov;85(11):2457-2459. doi: 10.1111/bcp.14079. Epub 2019 Sep 4. No abstract available.

PMID:
31486113
7.

Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology.

Rijsbergen M, Niemeyer-van der Kolk T, Rijneveld R, Pinckaers JHFM, Meshcheriakov I, Bouwes Bavinck JN, van Doorn MBA, Hogendoorn G, Feiss G, Cohen AF, Burggraaf J, van Poelgeest MIE, Rissmann R.

J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15872. [Epub ahead of print]

PMID:
31419338
8.

Sensitivity and specificity of detection methods for erythropoietin doping in cyclists.

Heuberger JAAC, van Eenoo P, Rotmans JI, Gal P, Stuurman FE, Post TE, Daniels JMA, Ram H, de Hon O, Burggraaf J, Cohen AF.

Drug Test Anal. 2019 Sep;11(9):1290-1301. doi: 10.1002/dta.2665. Epub 2019 Jul 17.

9.

Inappropriate Study Design Produces Spurious Effects of Autologous Blood Transfusion.

Heuberger JAAC, Cohen AF.

Med Sci Sports Exerc. 2019 Jul;51(7):1568. doi: 10.1249/MSS.0000000000001926. No abstract available.

PMID:
31205254
10.

A review of current approaches for evaluating impaired performance in around-the-clock medical professionals.

Huizinga CRH, Tummers FHMP, Marang-van de Mheen PJ, Cohen AF, van der Bogt KEA.

Sleep Med Rev. 2019 Aug;46:97-107. doi: 10.1016/j.smrv.2019.04.007. Epub 2019 Apr 25. Review.

PMID:
31102878
11.

Evaluation of simulated driving in comparison to laboratory-based tests to assess the pharmacodynamics of alprazolam and alcohol.

Huizinga CR, Zuiker RG, de Kam ML, Ziagkos D, Kuipers J, Mejia Y, van Gerven JM, Cohen AF.

J Psychopharmacol. 2019 Jul;33(7):791-800. doi: 10.1177/0269881119836198. Epub 2019 Mar 26.

PMID:
30912701
12.

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development.

Hart EP, Alvarez-Jimenez R, Davidse E, Doll RJ, Cohen AF, Van Gerven JMA, Groeneveld GJ.

J Vis Exp. 2019 Feb 11;(144). doi: 10.3791/56569.

PMID:
30799845
13.

Reply to Holgado et al.: Comment on "Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects".

Heuberger JAAC, Cohen AF.

Sports Med. 2019 Jul;49(7):1137. doi: 10.1007/s40279-019-01062-4. No abstract available.

PMID:
30689128
14.

Recombinant human erythropoietin does not affect several microvascular parameters in well-trained cyclists.

Birkhoff WAJ, Heuberger JAAC, Post TE, Gal P, Stuurman FE, Burggraaf J, Cohen AF.

Physiol Rep. 2018 Dec;6(24):e13924. doi: 10.14814/phy2.13924.

15.

Repeatability and predictive value of lactate threshold concepts in endurance sports.

Heuberger JAAC, Gal P, Stuurman FE, de Muinck Keizer WAS, Mejia Miranda Y, Cohen AF.

PLoS One. 2018 Nov 14;13(11):e0206846. doi: 10.1371/journal.pone.0206846. eCollection 2018.

16.

Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects.

Heuberger JAAC, Cohen AF.

Sports Med. 2019 Apr;49(4):525-539. doi: 10.1007/s40279-018-1014-1. Review.

17.

Futility of current urine salbutamol doping control.

Heuberger JAAC, van Dijkman SC, Cohen AF.

Br J Clin Pharmacol. 2018 Aug;84(8):1830-1838. doi: 10.1111/bcp.13619. Epub 2018 Jun 3.

18.

Evaluating Fitness to Perform in Surgical Residents after Night Shifts and Alcohol Intoxication: The development of a "Fit-to-Perform" test.

Huizinga CRH, de Kam ML, Stockmann HBAC, van Gerven JMA, Cohen AF, van der Bogt KEA.

J Surg Educ. 2018 Jul - Aug;75(4):968-977. doi: 10.1016/j.jsurg.2018.01.010. Epub 2018 Feb 2.

PMID:
29396276
19.

Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses.

Alvarez-Jimenez R, Hart EP, Prins S, de Kam M, van Gerven JMA, Cohen AF, Groeneveld GJ.

Br J Clin Pharmacol. 2018 May;84(5):888-899. doi: 10.1111/bcp.13507. Epub 2018 Feb 20.

20.

Pharmacological vs. classical approaches in the design of first in man clinical drug trials.

van den Bogert CA, Cohen AF, Leufkens HGM, van Gerven JMA.

Br J Clin Pharmacol. 2017 Dec;83(12):2807-2812. doi: 10.1111/bcp.13422. Epub 2017 Oct 6.

21.

Erythropoietin on cycling performance - Authors' reply.

Heuberger JAAC, Rotmans JI, Gal P, Stuurman FE, Daniels JMA, de Kam ML, Cohen AF.

Lancet Haematol. 2017 Oct;4(10):e462-e464. doi: 10.1016/S2352-3026(17)30181-3. No abstract available.

PMID:
28962681
22.

On authorship in the BJCP.

Cohen AF.

Br J Clin Pharmacol. 2017 Oct;83(10):2127-2130. doi: 10.1111/bcp.13385. No abstract available.

23.

Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial.

Heuberger JAAC, Rotmans JI, Gal P, Stuurman FE, van 't Westende J, Post TE, Daniels JMA, Moerland M, van Veldhoven PLJ, de Kam ML, Ram H, de Hon O, Posthuma JJ, Burggraaf J, Cohen AF.

Lancet Haematol. 2017 Aug;4(8):e374-e386. doi: 10.1016/S2352-3026(17)30105-9. Epub 2017 Jun 29.

PMID:
28669689
24.

[The life cycle of clinical drug research].

Cohen AF.

Ned Tijdschr Geneeskd. 2017;161:D1576. Dutch.

PMID:
28659211
25.

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients.

van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, Samuels S, Kenter GG, Cohen AF, Melief CJ, Burggraaf J, van Poelgeest MI, van der Burg SH.

Oncoimmunology. 2016 Dec 23;6(2):e1267095. doi: 10.1080/2162402X.2016.1267095. eCollection 2017.

26.

Clinical Pharmacology Research Internships at the Interface between Academia and Industry: Students' Perceptions and Scientific Output.

Goulooze SC, Franson KL, Cohen AF, Rissmann R.

Basic Clin Pharmacol Toxicol. 2017 Jul;121(1):22-28. doi: 10.1111/bcpt.12756. Epub 2017 Mar 8.

27.

Quantifying Beta-Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling.

Kanhai K, Goulooze SC, Stevens J, Hay JL, Dent G, Verma A, Hankemeier T, de Boer T, Meijering H, Chavez JC, Cohen AF, Groeneveld GJ.

Clin Transl Sci. 2016 Dec;9(6):321-327. doi: 10.1111/cts.12424. Epub 2016 Oct 15.

28.

European drug market entries 2015 with new mechanisms of action.

van den Heuvel TW, Cohen AF, Rissmann R.

Clin Med (Lond). 2016 Oct;16(5):475-480.

29.

Question-based Drug Development for psilocybin.

Dijkstra FM, Jacobs GE, Cohen AF.

Lancet Psychiatry. 2016 Sep;3(9):806-7. doi: 10.1016/S2215-0366(16)30214-0. No abstract available.

PMID:
27568265
30.

Sputum RNA signature in allergic asthmatics following allergen bronchoprovocation test.

Zuiker RG, Tribouley C, Diamant Z, Boot JD, Cohen AF, Van Dyck K, De Lepeleire I, Rivas VM, Malkov VA, Burggraaf J, Ruddy MK.

Eur Clin Respir J. 2016 Jul 13;3:31324. doi: 10.3402/ecrj.v3.31324. eCollection 2016.

31.

A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer.

Hoogstins CE, Tummers QR, Gaarenstroom KN, de Kroon CD, Trimbos JB, Bosse T, Smit VT, Vuyk J, van de Velde CJ, Cohen AF, Low PS, Burggraaf J, Vahrmeijer AL.

Clin Cancer Res. 2016 Jun 15;22(12):2929-38. doi: 10.1158/1078-0432.CCR-15-2640.

32.

Sofosbuvir and daclatasvir.

Hessel MH, Cohen AF, Rissmann R.

Br J Clin Pharmacol. 2016 Sep;82(3):878-9. doi: 10.1111/bcp.13011. Epub 2016 Jun 12. No abstract available.

33.

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH.

Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307.

PMID:
27075626
34.

Injection site reactions after subcutaneous oligonucleotide therapy.

van Meer L, Moerland M, Gallagher J, van Doorn MB, Prens EP, Cohen AF, Rissmann R, Burggraaf J.

Br J Clin Pharmacol. 2016 Aug;82(2):340-51. doi: 10.1111/bcp.12961. Epub 2016 May 31. Review.

35.

Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17.

Tummers QR, Hoogstins CE, Gaarenstroom KN, de Kroon CD, van Poelgeest MI, Vuyk J, Bosse T, Smit VT, van de Velde CJ, Cohen AF, Low PS, Burggraaf J, Vahrmeijer AL.

Oncotarget. 2016 May 31;7(22):32144-55. doi: 10.18632/oncotarget.8282.

36.

Implications of the BIA-102474-101 study for review of first-into-human clinical trials.

Eddleston M, Cohen AF, Webb DJ.

Br J Clin Pharmacol. 2016 Apr;81(4):582-6. doi: 10.1111/bcp.12920.

37.

Digoxin and mortality: lessons for observational studies.

de Boer A, Cohen AF.

Br J Clin Pharmacol. 2016 Jan;81(1):4-5. doi: 10.1111/bcp.12791. Epub 2015 Nov 20. No abstract available.

38.

Olaparib.

Goulooze SC, Cohen AF, Rissmann R.

Br J Clin Pharmacol. 2016 Jan;81(1):171-3. doi: 10.1111/bcp.12761. Epub 2015 Oct 24.

39.

Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.

van Poelgeest EP, Hodges MR, Moerland M, Tessier Y, Levin AA, Persson R, Lindholm MW, Dumong Erichsen K, Ørum H, Cohen AF, Burggraaf J.

Br J Clin Pharmacol. 2015 Dec;80(6):1350-61. doi: 10.1111/bcp.12738. Epub 2015 Oct 24.

40.

Need for a proactive and structured approach to risk analysis when designing phase I trials.

Van den Bogert CA, Cohen AF.

BMJ. 2015 Jul 22;351:h3899. doi: 10.1136/bmj.h3899. No abstract available.

PMID:
26201349
41.

Reproducibility of biomarkers in induced sputum and in serum from chronic smokers.

Zuiker RG, Kamerling IM, Morelli N, Calderon C, Boot JD, de Kam M, Diamant Z, Burggraaf J, Cohen AF.

Pulm Pharmacol Ther. 2015 Aug;33:81-6. doi: 10.1016/j.pupt.2015.05.001. Epub 2015 May 9.

PMID:
25966831
42.

Vemurafenib/dabrafenib and trametinib.

Rissmann R, Hessel MH, Cohen AF.

Br J Clin Pharmacol. 2015 Oct;80(4):765-7. doi: 10.1111/bcp.12651. Epub 2015 Jun 11. No abstract available.

43.

Mirabegron.

Goulooze SC, Cohen AF, Rissmann R.

Br J Clin Pharmacol. 2015 Oct;80(4):762-4. doi: 10.1111/bcp.12647. Epub 2015 Jun 5.

44.

The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology.

Kenter MJ, Cohen AF.

Br J Clin Pharmacol. 2015 Apr;79(4):545-7. doi: 10.1111/bcp.12605. No abstract available.

45.

Bedaquiline.

Goulooze SC, Cohen AF, Rissmann R.

Br J Clin Pharmacol. 2015 Aug;80(2):182-4. doi: 10.1111/bcp.12613. Epub 2015 Jul 2. No abstract available.

46.

Lomitapide.

Goulooze SC, Cohen AF, Rissmann R.

Br J Clin Pharmacol. 2015 Aug;80(2):179-81. doi: 10.1111/bcp.12612. Epub 2015 Jul 2. No abstract available.

47.

BJCP 40th anniversary: moving forward, looking back.

Gilchrist A, Loke YK, Somogyi AA, Cohen AF, Ritter JM.

Br J Clin Pharmacol. 2014 Dec;78(6):1175-84. doi: 10.1111/bcp.12520. No abstract available.

48.

Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Heuberger JA, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, van Gerven JM, Cohen AF, Freijer J.

Clin Pharmacokinet. 2015 Feb;54(2):209-19. doi: 10.1007/s40262-014-0195-5.

PMID:
25316574
49.

The use of biomarkers in human pharmacology (Phase I) studies.

Cohen AF, Burggraaf J, van Gerven JM, Moerland M, Groeneveld GJ.

Annu Rev Pharmacol Toxicol. 2015;55:55-74. doi: 10.1146/annurev-pharmtox-011613-135918. Epub 2014 Oct 6. Review.

PMID:
25292425
50.

First proof of pharmacology in humans of a novel glucagon receptor antisense drug.

van Dongen MG, Geerts BF, Morgan ES, Brandt TA, de Kam ML, Romijn JA, Cohen AF, Bhanot S, Burggraaf J.

J Clin Pharmacol. 2015 Mar;55(3):298-306. doi: 10.1002/jcph.396. Epub 2014 Sep 15.

PMID:
25197025

Supplemental Content

Loading ...
Support Center